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ABSTRACT 
There is an obvious need for a critical discussion of the concepts ‘placebo’ 
and ‘placebo effect’. In a recent paper on the use of placebos in clinical 
medicine, Gold and Lichtenberg note the conceptual difficulties but use 
the terminology in a confused way throughout their paper. In our response, 
we demonstrate these problems with a few examples from their paper. 
____________________________________________________________
Gold and Lichtenberg provide an interesting discussion about the use of placebos in clinical 
medicine (1). We agree with several of their statements, for example, “We cannot speak of 
placebo, or of any treatment for that matter, divorced from its psychosocial context” (p. 219).
We also appreciate their careful philosophical analysis on deception and autonomy as related 
to the potential clinical use of placebos. 
The authors note the conceptual difficulties related to placebos and placebo effects, 
and they redefine the essential question without using the term ‘placebo’: “when is it ethical, 
in clinical practice, to offer a therapeutic intervention, when the effect, if any, of that 
intervention is expected to be mediated by psychophysiological mechanisms, such as 
expectation, relaxation or conditioned response” (p. 220). 
Unfortunately, however, the authors ignore the conceptual difficulties and use the 
terminology in a confused way throughout their paper. Therefore, we wish to point out 
a few examples of the problems they have with their use of the term ‘placebo’: 
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The placebo is arguably the most commonly prescribed drug, 
across cultures and throughout history. (p. 219) 
Comment: This statement is grossly misleading. Some treatments have been, and still are, 
ineffective, but using an ineffective treatment does not mean that the physician is using a 
placebo. The term ‘placebo’ implies that the physician knows that the treatment as such is 
ineffective but uses it anyway. If we find out that a standard treatment was not effective after 
its use, labelling the treatment a placebo is not justified. Furthermore, claiming that placebos 
are widely used presupposes the broad umbrella concept ‘placebo’, which is divided into 
‘pure placebo’ and ‘impure placebo’, as has been done in several recent research papers (2–4). 
The latter concept is problematic and not at all helpful in understanding current or historical 
practices (5).
Physicians are reluctant to add even potentially 
effective placebos to their therapeutic arsenal. (p. 219) 
Comment: Gold and Lichtenberg do not describe what they mean with a ‘potentially effective 
placebo’. If there is such a category, there should also logically exist ‘potentially ineffective 
placebos’, ‘actually effective placebos’ and ‘actually ineffective placebos’. Here the authors 
forget the crucial importance of context, although they emphasise it in the quotation mentioned 
in our first paragraph. 
The 15–80% of physicians who use placebo treatments ... (p. 223) 
Comment: Again, this statement presupposes the concept ‘impure placebo’, which is a very 
vague category (5,6). For example, according to the recent survey by Howick et al, 97% of GPs 
had used ‘impure placebos’ in contrast to 12% of the GPs who had used ‘pure placebos’ at least 
once during their career (2). Only 1% of the respondents reported using ‘pure placebos’ at least 
once per week. Thus, the 15–80% mentioned by Gold and Lichtenberg does not refer to the use 
of ‘pure placebos’. According to figures of Howick et al (defined by “at least once in their 
career”/“at least once per week”), it is not possible to estimate the actual prevalence of the use of
pure placebos (ie, how great a proportion of patients has received ‘impure’ or ‘pure placebos’). 
Furthermore, there is no meaningful interpretation for the result that 97% of the GPs reported 
using ‘impure placebos’ since the term covers a large variety of treatments and other activities, 
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from antibiotics for suspected viral infections to vitamins without approved indications 
and from positive suggestions to unnecessary referrals (2,5).
Nevertheless, it is important to mention that, according to an influential 2001 
meta-analysis comparing placebo-treatment arms with no treatment, 
placebos make no clinical difference (ref. 20). (p. 220)
Comment: This statement is false. The abstract of ref. 20 states: “In 27 trials involving the 
treatment of pain, placebo had a beneficial effect (−0.27; 95% CI −0.40 to −0.15)” (7). Such 
a particularly narrow (far from null effect) 95% CI implies very strong evidence of an effect 
on pain in the placebo arms of the trial. 
The physicians prescribe placebos ... (p. 219). 
Administration of placebos ... (p. 223) 
Comment: The authors do not describe what they mean by such interventions in practice. 
Do Gold and Lichtenberg propose that (pure) placebos should be commercially available or that 
physicians should produce placebo tablets themselves to be given to their own patients? If a 
physician ‘prescribes placebos’, what does he or she actually write in the prescription? We agree 
that, at the office, a physician can select words so that he or she is not caught in a lie or 
deception. However, what kind of prescription will the patient have in his or her hands when 
leaving the office? Furthermore, how will the physician respond later if or when the patient finds
out that “I am prescribing a pill which research suggests can be of benefit to you...” (p. 221) 
actually means an inert substance called placebo? Nowadays the patient can rapidly search the 
internet to find out what the term ‘placebo’ means even if the term was not familiar earlier. 
If physicians start using inert substances to increase the ‘placebo effect’, and their 
patients learn about such a practice, the physicians may lose trust, which is an essential part of 
the doctor–patient relationship, as mentioned also by Gold and Lichtenberg (p. 223). Keeping or 
losing trust does not depend on a philosophical classification of the statement of the physician as
a lie or deception (p. 220). It is the patient who decides whether he or she trusts the physician 
irrespective of philosophers’ opinions outside a particular doctor–patient relationship. 
There is an obvious need for a critical discussion of the concepts ‘placebo’ and ‘placebo effect’ 
(8–11). The preceding examples from the paper by Gold and Lichtenberg are another 
demonstration of that need. 
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